Table 3.
Unadjusted Changes in KCCQ Among Patients With Complete Follow-Up Data
| Overall | HG-AS | NF-LG AS | Classical LF-LG AS | Paradoxical LF-LG AS |
P Value |
||
|---|---|---|---|---|---|---|---|
| Overall | HG vs NF-LG | ||||||
| Complete KCCQ data | 530a (61.6) | 245a (66.6) | 140 (57.1) | 45 (60.8) | 100 (57.8) | ||
| Baseline KCCQ-12 | 49.5 ± 24.8 | 51.3 ± 26.2 | 51.1 ± 22.2 | 45.9 ± 27.9 | 44.3 ± 22.3 | 0.061 | 0.918 |
| Follow-up KCCQ-12 | 73.5 ± 23.3 | 76.2 ± 23.2 | 73.3 ± 22.0 | 68.6 ± 27.1 | 69.3 ± 22.6 | 0.032 | 0.219 |
| ΔKCCQ-12 | 24.0 ± 24.8 | 24.9 ± 27.5 | 22.2 ± 21.6 | 22.7 ± 25.5 | 25.0 ± 21.6 | 0.722 | 0.318 |
| Complete end point data | 615 (71.5) | 267 (72.6) | 169 (69.0) | 53 (71.6) | 126 (72.8) | ||
| Achieving primary endpoint (1 y survival with ΔKCCQ ≥5) | 417 (67.8) | 188 (70.4) | 108 (63.9) | 33 (62.3) | 88 (69.8) | 0.393 | 0.189 |
Values are n (%) or mean ± SD. Baseline, follow-up and ΔKCCQ includes only those with complete KCCQ follow-up. Achieving primary end point includes all patients that had complete endpoint data (death within 1 year or 1-year follow-up KCCQ score); percentages are based on the total number of patients with available end point follow-up data.
AS = aortic stenosis; HG = high-gradient; KCCQ = Kansas City Cardiomyopathy Questionnaire; LF-LG = low-flow, low-gradient; NF-LG = normal-flow, low-gradient.
a
Follow-up KCCQ data were reported for one patient who died within the 1-year follow-up, with available follow-up KCCQ performed at 310 days post-TAVR.